FDA Approved: ZARXIO — Supplemental Application (Sandoz Inc.)

View source ↗

Summary

FDA approved a supplemental application for Zarxio (filgrastim-sndz) filed by Sandoz Inc., resulting in labeling changes under the supplemental submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Chemotherapy-induced Neutropenia
• Neutropenia

Drugs mentioned

• ZARXIO (FILGRASTIM-SNDZ)

Snippet

SUPPL AP for ZARXIO (FILGRASTIM-SNDZ)